Systemic Sclerosis (SSc) Education

Dr. Tracy Frech, a rheumatologist from the University of Utah discusses her work with Corbus Pharmaceuticals to address systemic sclerosis (SSc) through a disease state education program with a new website geared towards physicians.  The program will provide resources to better equip them for treating their patients and understanding the need to address the totality of SSc, a rare, complex and debilitating disease.

Read More

Medicago Biopharmaceuticals – Plant-based COVID-19 vaccine candidate

Dr. Bruce Clark, CEO of Medicago, a biopharmaceutical company headquartered in Quebec City, and a leader in plant-based technology, discusses the announcement on March 12, 2020, that they had successfully produced a Virus-Like Particle (VLP) of the corona virus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene using plant-based technology.  Production of the VLP is the first step in developing a vaccine for COVID-19, which will now undergo preclinical testing for safety and efficacy. Once this is completed, Medicago expects to discuss with the appropriate Health Agencies to initiate human trials of the vaccine by summer (July/August) 2020.

Read More

Chronic Kidney Disease (CKD) and Gout

Dr. Payam Shakouri, a nephrologist, discusses uncontrolled gout and its connection to chronic kidney disease (CKD).  Approximately 1 in 4 adults with CKD has gout. It’s 10x more likely for a person with moderate-to-severe CKD to have gout than someone who does not.

Read More

Patient with chronic kidney disease and gout

Adam Cogar, a kidney transplant recipient, talks about his 15-year journey to a diagnosis of uncontrolled gout.  He discusses how the pain had impacted his daily life and how different his life is now that he has a clear diagnosis, treatment plan in place, and can manage his condition.  The prevalence of gout is more than ten-fold greater among patients who have undergone a kidney transplant than the general population.

Read More

Incyte Ingenuity Award for graft versus host disease

Incyte, a global biopharmaceutical company announces its opening call for submissions for its new Incyte Ingenuity Award. a program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians.  GVHD is a potentially life-threatening condition that can occur after a stem cell or bone marrow transplant from a donor initiate an immune response and attack the transplant recipient’s organs. Here to talk about Incyte’s dedication to the program is Incyte’s Executive Vice President, General Manager, United States, Dr. Barry Flannelly.  The program is expected to fund up to $100,000 a year for one innovative program or idea.

Read More

SyTrue, Inc., NLP OS™ Platform

Kyle Silvestro, CEO of the healthcare software company SyTrue, Inc., discusses SyTrue’s Natural Language Processing (NLP) Operating System (OS) NLP OS™ and how they are offering their services for free for COVID-19 studies. He also talks about SyTrue’s partnering with Microsoft.

Read More

Genomic Medicines – Sangamo Therapeutics Inc

Dr. Bettina Cockroft, M.D., SVP and CMO at Sangamo Therapeutics, Inc., a genomic medicine company, discusses their approach to treating disease and why genomic medicines are so important to the future of medicine.  She also talks about one of the latest therapies Sangamo has in a Phase 1/2 clinical trial for the treatment of Fabry disease, a rare, X-linked lysosomal storage disorder caused by a gene mutation in an enzyme responsible for breaking down fatty substances.

Read More